Trials / Completed
CompletedNCT07124013
A Study of Olomorasib (LY3537982) in Healthy Japanese Participants
An Open-Label, Phase 1 Study to Investigate the Comparability of the Pharmacokinetics of Olomorasib (LY3537982) Between Two Capsule Formulations and to Evaluate the Food Effect in Healthy Japanese Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 191 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare and see how food affects the amount of olomorasib in the blood when olomorasib is taken in two different capsule forms. Participation in the study will last approximately 6 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olomorasib | Administered orally |
Timeline
- Start date
- 2025-09-16
- Primary completion
- 2026-01-05
- Completion
- 2026-01-05
- First posted
- 2025-08-15
- Last updated
- 2026-01-16
Locations
1 site across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07124013. Inclusion in this directory is not an endorsement.